Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study.

[1]  J. Hollingsworth,et al.  Prostatic fibrosis is associated with lower urinary tract symptoms. , 2012, The Journal of urology.

[2]  R. Hayes,et al.  Non‐steroidal anti‐inflammatory drug use and the risk of benign prostatic hyperplasia‐related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2012, BJU international.

[3]  T. Nguyen,et al.  Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP‐1/CCL2 and VCAM‐1, in vitro , 2012, BJU international.

[4]  G. Norstedt,et al.  Androgen‐independent Effects of Serenoa repens Extract (Prostasan®) on Prostatic Epithelial Cell Proliferation and Inflammation , 2012, Phytotherapy research : PTR.

[5]  F. Schröder,et al.  The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. , 2011, European urology.

[6]  S. Terry,et al.  Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis , 2009, The Prostate.

[7]  Y. Allory,et al.  Should We Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia , 2009 .

[8]  Marco Bianchi,et al.  Benign Prostatic Hyperplasia and Its Aetiologies , 2009 .

[9]  E. Platz,et al.  Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. , 2009, Current opinion in pharmacology.

[10]  L. Adorini,et al.  Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. , 2009, International journal of andrology.

[11]  M. Gyetko,et al.  Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. , 2009, Current medicinal chemistry.

[12]  D. Bostwick,et al.  The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. , 2008, European urology.

[13]  H. Ellingsgaard,et al.  Islet Inflammation in Type 2 Diabetes , 2008, Diabetes Care.

[14]  A. Sciarra,et al.  Inflammation and chronic prostatic diseases: evidence for a link? , 2007, European urology.

[15]  H. Hoshi,et al.  Comparison of urethral diameters for calculating the urethral dose after permanent prostate brachytherapy , 2007, Radiation Medicine.

[16]  G. Kramer,et al.  Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? , 2007, European urology.

[17]  J. S. St. Sauver,et al.  Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. , 2006, American journal of epidemiology.

[18]  B. Sipos,et al.  Pancreatic fibrosis associated with age and ductal papillary hyperplasia , 2005, Virchows Archiv.

[19]  C. Roehrborn,et al.  1277: The Impact of Acute or Chronic Inflammation in Baseline Biopsy on the Risk of Clinical Progression of BPH: Results from the MTOPS Study , 2005 .

[20]  D. Peehl,et al.  Molecular and cellular pathogenesis of benign prostatic hyperplasia. , 2004, The Journal of urology.

[21]  A. Farré,et al.  BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. , 2003, European urology.

[22]  A. Sciarra,et al.  Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. , 2003, European urology.

[23]  Downey,et al.  Asymptomatic inflammation and/or infection in benign prostatic hyperplasia , 1999, BJU international.

[24]  J. Goujon,et al.  Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. , 1997, The Journal of urology.

[25]  W. Schäfer,et al.  Principles and clinical application of advanced urodynamic analysis of voiding function. , 1990, The Urologic clinics of North America.

[26]  S. Kaplan,et al.  Role of inflammation in benign prostatic hyperplasia. , 2011, Reviews in urology.

[27]  C. Bosman,et al.  Combination Therapy with Rofecoxib and Finasteride in the Treatment of Men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH) , 2005 .

[28]  P. Abrams,et al.  The Abrams-Griffiths nomogram , 2004, World Journal of Urology.

[29]  T. Koyanagi,et al.  Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy , 2004, The Prostate.

[30]  P. Abrams,et al.  Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure‐flow studies * * , 2002, Neurourology and urodynamics.